61MO IMscin001 (part 2: randomized phase III): Pharmacokinetics (PK), efficacy and safety of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC)
Autor: | M. Burotto, Z. Zvirbule, A. Mochalova, Y. Runglodvatana, L.A. Herraez Baranda, S. Liu, P. Chan, E. Shearer-Kang, M. Shivhare, N. Tosti, J. Zanghi, B. Leutgeb, E. Felip |
---|---|
Rok vydání: | 2022 |
Předmět: | |
Zdroj: | Immuno-Oncology and Technology. 16:100166 |
ISSN: | 2590-0188 |
Databáze: | OpenAIRE |
Externí odkaz: |